Executive Management

Dr. Todd M. Fruchterman is President and Chief Executive Officer at Butterfly Network. As both a physician and a leader in medical technology, he has dedicated his career to promoting health and wellness through innovation. He joined the company in 2021 to advance Butterfly's core mission of enabling universal access to superior medical imaging by making high quality ultrasound affordable, easy-to-use, globally accessible and intelligently connected.

He spent nearly ten years of his career at 3M Company (“3M”) where he held multiple roles, most recently as the President and General Manager of Medical Solutions at 3M, the largest division in the company, where he achieved global above-market, profitable growth and delivered transformational acquisitions. In his 23-year career, Dr. Fruchterman has held senior leadership positions at Kinetic Concepts, Inc., and Response Genetics, Inc., and also has held various positions of increasing responsibility at Johnson & Johnson and Schering-Plough. His broad-based experience spans the clinical, scientific, regulatory, and business arenas. In industry he has focused on creating value in businesses with a passion for creative problem solving, innovation and excellence in execution, and has successfully commercialized and scaled disruptive technologies throughout his career.

Dr. Fruchterman holds 11 patents, has served on the board of directors of AdvaMed, and in 2019, was a core participant in the U.S. Department of HHS Deputy Secretary’s Innovation and Investment Summit. He is also a business advisor at Spindletop Capital, LLC and has served on the Leonard Davis Institute of Health Economics Executive Advisory Board, the Executive Committee of BioMed SA of San Antonio, the Board of Directors for LifeScience Alley and the Board of Directors of the Texas Life Science Center. He received his Bachelor of Arts in Biological Basis of Behavior and Medical Doctorate degrees from the University of Pennsylvania, and his Ph.D. in Physiology and Biophysics at the University of Louisville, Kentucky.

Heather Getz is the Chief Financial Officer at Butterfly Network, Inc., where she oversees all aspects of corporate finance, investor relations and accounting. Previously, Getz was Executive Vice President and Chief Financial and Administrative Officer at BioTelemetry, Inc., a publicly traded remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care.

Heather has 25 years of experience spanning both public and private companies, with a strong background in the digital health and medical device space. She has a history of contributing to the creation of long-term company value, driving operational excellence, and accelerating profitability. During her tenure at BioTelemetry, the company saw an increase in market capitalization of over $2.5 billion, culminating with a sale to Royal Philips in 2021. Before this, Heather held various financial leadership positions at companies including Alita Pharmaceuticals, VIASYS Healthcare, and Sunoco

Heather holds an M.B.A. and a B.A. in Accountancy from Villanova University. She is a certified public accountant and is a member of the American Institute of Certified Public Accountants, the Pennsylvania Institute of Certified Public Accountants and the National Investor Relations Institute. She has served on the Board of Directors of ADEA, a privately held healthcare company based in Sweden from 2018 to 2021. In 2013, Getz was recognized by the Philadelphia Business Journal and Drexel University’s LeBow College of Business as a CFO of the Year, Large Company Finalist. Getz was also a co-facilitator of BioTelemetry’s leadership program offered to high-potential employees and senior leaders in the organization.

Dr. John Martin is the Chief Medical Officer of Butterfly Network, a transformational medical device company that is democratizing medical imaging across the globe.

Dr. Martin completed a residency in general surgery and vascular surgery at Parkland Memorial Hospital in Dallas Texas. He is board certified in vascular surgery and a Fellow of the American College of Surgeons. He served in the United States Air Force for 7 years first as a corpsman and then after completing medical school and training he returned as a Surgeon.

He has held multiple positions throughout his career including Chief of Vascular Surgery and Director of Heart and Vascular Services at Anne Arundel Medical Center, President of Cardiology Associates, and Vice President of Physician Operations for MedStar Medical Group.

He is the founder and President of the Heart Health Foundation and the award-winning Dare to CARE Program. He is the author of multiple peer reviewed papers and book chapters, holds several patents and developed clinical software used across the country. An often-requested speaker, his most recent events include Wall Street Journal Live in Hong Kong and TedMed.

Stacey Pugh is the Chief Commercial Officer at Butterfly Network. As a leader in Medical Technology, she has more than 15 years of experience in medical device research, development and commercialization. Stacey joined Butterfly in 2021 and will lead the company in the planning, organization, and implementation of all sales and marketing activities.

Prior to Butterfly, Stacey was President of Medtronic’s Neurovascular Operating Unit, where she provided overall global strategic leadership, guided marketing and business development and was responsible for revenue growth. Prior to this role, Stacey was Vice President and General Manager of Neurovascular & Cerebral Spinal Fluid (CSF) businesses and was responsible for leading the company’s European, Middle Eastern and African (EMEA) business programs and developing trade strategies to support the global revenue and market share growth of Medtronic Neurovascular products.

In addition, Stacey held various leadership roles in Covidien’s Neurovascular division as Vice President of Global Medical Affairs where she provided strategic direction for all medical affairs activities and executed strategic market access plans.

As a registered nurse, Stacey spent the early years of her career in research, critical care and trauma nursing, and nursing education.

Troy Quander is a Regulatory Professional with over 25 years of FDA and Industry experience with a Focus on Regulatory Affairs, Regulatory Compliance, and Quality.Prior to Butterfly, Troy was at Olympus, where he was the Vice President of Regulatory Affairs, and responsible for global regulatory strategy development and execution for the Medical Device Business Segment. Before Olympus, Troy held Vice President Leadership roles for Regulatory Affairs and Quality for Roche Diagnostics. In addition, he has held leadership roles of increasing responsibilities at Becton Dickinson, OraSure Technologies, Johnson & Johnson, and bioMerieux. Troy spent part of his career with the Food and Drug Administration’s Center for Biologics Evaluation and Research, as a Product Reviewer and Product Specialist for Team Biologics, where he performed submission reviews of in vitro diagnostics and conducted facility inspections. He holds a bachelor’s degree in Biology from Lincoln University.

Darius is Chief Strategy Officer and Chief Business Development Officer at Butterfly Network (MedTech Unicorn), where he helps lead the company's fundraising, global health, commercial and strategic efforts. In 2018, and while a student at HBS, Darius raised $250 million dollars for Butterfly Network - the largest medical imaging raise in history.

Prior to coming to HBS, Darius was Head of Trading at Birch Grove Capital, a Global Cross-Asset Hedge Fund which manages over $1BN. In this capacity he was responsible for all trading across Credit, Equities, Convertibles, Bank Debt and Commodities as well as helping the CIO in risk and portfolio management.

Prior to Birch Grove, Darius built the Cross Asset Special Situations Desk at Morgan Stanley, where he was amongst the firm’s youngest hires. In this role, he was responsible for sourcing and structuring over $1BN in banking transactions and acted as the Firm’s specialist on Argentina during the default proceedings.

Darius holds a MBA from Harvard Business School and a B.S from Duke University, where he studied Neuroscience and Psychology, and worked for Dan Ariely, one of the world’s foremost Behavioral Economists. He speaks five languages, holds three passports and has lived and worked in New York, London, Buenos Aires and São Paulo.

Dr. Stoica is the Chief Technology Officer at Butterfly Network. In this role, he leads the company’s technology and product development operations. Prior to Butterfly Network, Dr. Stoica was the Chief Technology Officer for BioTelemetry, a leading remote cardiac monitoring company serving over 1 million patients a year.

At BioTelemetry Dr Stoica was responsible for hardware and software product development, product management, enterprise, and product information technology, as well as product manufacturing and distribution. In 2021 BioTelemetry was acquired by Philips.

Prior to BioTelemetry, Dr. Stoica held various leadership positions at IQVIA, with the last position as Senior Vice President, Systems Development. In that role he led the development of the company’s Data Cloud Platform. The Data Cloud supported the largest data brokerage business in the world, operated one of the top 20 private data clouds, it had over 120,000 data suppliers, and it managed more than 1 million data streams in over 100 countries.

Dr. Stoica’s other appointments include information technology positions in the health IT industry as well as research and teaching positions in academia. Dr. Stoica holds a Ph.D. in Computer Science and Engineering from the University of South Carolina.